Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
Radiology ; 298(2):E81-E87, 2021.
Article | WHO COVID | ID: covidwho-1048702


Background The role and performance of chest CT in the diagnosis of the coronavirus disease 2019 (COVID-19) pandemic remains under active investigation Purpose To evaluate the French national experience using chest CT for COVID-19, results of chest CT and reverse transcription polymerase chain reaction (RT-PCR) assays were compared together and with the final discharge diagnosis used as the reference standard Materials and Methods A structured CT scan survey (NCT04339686) was sent to 26 hospital radiology departments in France between March 2, 2020, and April 24, 2020 These dates correspond to the peak of the national COVID-19 epidemic Radiology departments were selected to reflect the estimated geographic prevalence heterogeneities of the epidemic All symptomatic patients suspected of having COVID-19 pneumonia who underwent both initial chest CT and at least one RT-PCR test within 48 hours were included The final discharge diagnosis, based on multiparametric items, was recorded Data for each center were prospectively collected and gathered each week Test efficacy was determined by using the Mann-Whitney test, Student t test, chi2 test, and Pearson correlation coefficient P < 05 indicated a significant difference Results Twenty-six of 26 hospital radiology departments responded to the survey, with 7500 patients entered;2652 did not have RT-PCR test results or had unknown or excess delay between the RT-PCR test and CT After exclusions, 4824 patients (mean age, 64 years +/- 19 [standard deviation], 2669 male) were included With final diagnosis as the reference, 2564 of the 4824 patients had COVID-19 (53%) Sensitivity, specificity, negative predictive value, and positive predictive value of chest CT in the diagnosis of COVID-19 were 2319 of 2564 (90%;95% CI: 89, 91), 2056 of 2260 (91%;95% CI: 91, 92), 2056 of 2300 (89%;95% CI: 87, 90), and 2319 of 2524 (92%;95% CI: 91, 93), respectively There was no significant difference for chest CT efficacy among the 26 geographically separate sites, each with varying amounts of disease prevalence Conclusion Use of chest CT for the initial diagnosis and triage of patients suspected of having coronavirus disease 2019 was successful © RSNA, 2021 Online supplemental material is available for this article

Bone Marrow Transplant ; : 1-9, 2020.
Article | WHO COVID | ID: covidwho-939434


The COVID-19 pandemic has serious implications also for patients with other diseases Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry Especially, we cover the development of PBSC and bone marrow collection figures, donor management including Health and Availability Check (HAC), transport and cryopreservation of stem cell products, donor recruitment and business continuity measures The total number of stem cell products provided declined by around 15% during the crisis with a particularly strong decrease in bone marrow products We modified donor management processes to ensure donor and product safety HAC instead of confirmatory typing was helpful especially in countries with strict lockdowns New transport modes were developed so that stem cell products could be safely delivered despite COVID-19-related travel restrictions Cryopreservation of stem cell products became the new temporary standard during the pandemic to minimize risks related to transport logistics and donor availability However, many products from unrelated donors will never be transfused DKMS discontinued public offline donor recruitment, leading to a 40% decline in new donors during the crisis Most DKMS employees worked from home to ensure business continuity during the crisis